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aNeurobiology and Developmental Biology Laboratory, Pontifical Catholic University, Porto Alegre, RS, Brazil
bHealth Basic Science Department, Federal University of Medical Science, Porto Alegre, RS, Brazil
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Abstract. The present study was aimed to investigate neuropathological changes in AβPP/PS1 transgenic mice (Tg), as a model of
Alzheimer’s disease, subjected to supplementary iron administration in a critical postnatal period, in order to reveal the interaction
of genetic and environmental risk factors in the pathogenesis of the disease. Twelve Tg and 10 wild-type (Wt) littermates were
administered iron between the 12th and 14th post-natal days (TgFe, WtFe); 11 Tg and 15 Wt received vehicle (sorbitol 5%) alone
in the same period (TgSb, WtSb). Mice were killed at the age of six months and processed for morphological and biochemical
studies. No modifications in amyloid-β burden were seen in iron-treated and non-iron-treated AβPP/PS1 mice. No differences
in microglial reactions were observed when comparing the four groups of mice. Yet increased astrocytosis, as revealed by
densitometry of GFAP-immunoreactive astrocytes, and increased expression levels of GFAP, as revealed by gel electrophoresis and
western blotting, were found in iron-treated mice (both Tg and Wt) when compared with TgSb and WtSb. This was accompanied
by significant changes in brain fatty acid composition in AβPP/PS1 mice that led to a lower membrane peroxidizability index and
to reduced protein oxidative damage, as revealed by reduced percentages of the oxidative stress markers: glutamic semialdehyde,
aminoadipic semialdehyde, Nε-carboxymethyl-lysine, Nε-carboxyethyl-lysine, and Nε-malondialdehyde-lysine. These findings
demonstrate that transient dietary iron supplementation during the neonatal period is associated with cellular and metabolic
imprinting in the brain in adult life, but it does not interfere with the appearance of amyloid plaques in AβPP/PS1 transgenic
mice.
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INTRODUCTION
The number of elderly has risen with the increase of
life expectancy and,as a consequence, the prevalence of
age-related diseases including neurodegenerative dis-
orders has increased as well [1]. Neuropathological
changes in many degenerative diseases of the nervous
system are characterized by the presence of abnormal
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proteins which accumulate in the brain, leading to a se-
lective loss of neurons in an age-dependent manner [1–
3]. Alzheimer’s disease (AD) is the leading cause of
dementia in the elderly [1,2,4]. AD is a multisystemic
disease involving the neuronal circuits in the entorhi-
nal and perirhinal cortex, hippocampal complex, amyg-
dala, and neocortex, together with the basal forebrain
cholinergic system, striatum, thalamus, and several nu-
clei of the brain stem. The neuropathological hall-
marks of AD are extracellular deposits of amyloid-β
peptides (Aβ) consisting of diffuse or neuritic plaques,
and amyloid angiopathy; and intraneuronal deposits of
hyperphosphorylated tau manifested as neurofibrillary
pre-tangles and tangles, dystrophic neurites of neuritic
plaques, and neuropil threads [1–4]. Sporadic AD is a
common multifactor complex disorder resulting from
the interaction of both genetic (e.g., APOE) and envi-
ronmental factors in aged individuals [4–6]. Familial
AD is a very rare autosomal dominant disease, often
with early onset, caused by mutations in the amyloid-β
protein precursor and presenilin genes (AβPP, PSEN1,
PSEN2) both linked to Aβ metabolism [3–5].
Several transgenic animal models have been pro-
duced to recapitulate particular aspects of AD. AβPP/
PS1 transgenic mice overexpress both mutant human
AβPP and PS1 and show early and extensive Aβ de-
position in the form of plaques and amyloid angiopa-
thy [7–9]. AβPP/PS1 transgenic mice show progres-
sive amyloid plaque formation, dendritic spine loss,
astrocytosis, and behavioral deficiencies [10–13].
Increasing evidence shows that, in spite of vital phys-
iological functions, iron may play a role in metal-ion-
mediated oxidative damage under certain conditions,
most clearly pronounced with aging [14–20]. Accu-
mulation of proteins related with iron storage as fer-
ritin and hemosiderin occurs in the hippocampus, and
probably other regions, in AD [21]. However, regions
undergoing degeneration display an excess of iron rel-
ative to ferritin levels which may indicate that iron ac-
cumulates at a faster rate than ferritin is produced [22].
Moreover, iron-activated Aβ and plaque formation in-
duces activation of microglia and reactive astrocyto-
sis [22]. Furthermore, iron co-localizes with Aβ in
amyloid plaques in AβPP/PS1 transgenic mice [23].
Several studies have shown that neonatal iron expo-
sure may induce neurobehavioral and cognitive dys-
functions in adult mice [24,25]. Similar deficits are
observed in adult rats after postnatal iron administra-
tion [26–30]. These effects are reversed by selegi-
line [30] and the iron chelator desferoxamine [28]. In
these models, iron is given orally during the period of
maximal iron uptake by the brain so that the rodent
models mimic dietary iron supplementation to human
infants [28].
The present study was designed to investigate
histological and biochemical modifications in adult
AβPP/PS1 transgenic mice subjected to transient iron
administration at a critical postnatal period. The main
objective was to evaluate the interaction of genetic and
environmental factors in the pathology of the disease.
MATERIAL AND METHODS
Animal treatment
Twenty three 6-month-old AβPP/PS1 transgenic
mice (Tg) from the Jackson Laboratory (Bar Harbor,
Maine, USA) and 25 age-matched littermate control
mice (Wt) were used. The mouse line used in this
study expressed a Mo/Hu AβPP695swe construct in
conjunction with the exon-9-deleted variant of human
presenilin 1 (PS1-dE9) [8]. Details of neuropatholog-
ical and behavioral aspects of these mice are reported
elsewhere [11,13].
Twelve Tg and 10 Wt were subjected to iron ad-
ministration between the 12th and the 14th postnatal
days (TgFe, WtFe); 11 Tg and 15 Wt received vehi-
cle alone during the same period (TgSb, WtSb). The
neonatal iron treatment was performed as previously
described [24–30]. Briefly, 12-day-old mouse pups re-
ceived a single oral daily dose (10.0 ml/kg solution vol-
ume) of vehicle (5% sorbitol in water) (control group)
or 10.0 mg/kg of body weight of iron carbonyl (Sigma;
iron concentration in the solution was 1.0 mg/ml) via
a metallic gastric tube for 3 days. All the process was
conducted with the approval of the Committee for An-
imal Care and Research of the Autonomous Govern-
ment of Catalunya.
Immunohistochemical analyses (IHQ)
Three TgFe, 3 TgSb, 4 WtFe, and 4 WtSb 6-month
old mice were perfused through the left cardiac ventri-
cle for 20 min with 4% paraformaldehyde in phosphate
buffer. The brains were rapidly removed and immersed
in the same fixative solution at room temperature. Im-
mediately afterwards, the brains were cut sagitally and
embedded in paraffin. Serial, 5-µm-thick coronal sec-
tions were obtained with a microtome and used for
immunohistochemistry. De-waxed sections were im-
mersed in 3% hydrogen peroxide in 100% methanol
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for 15 min to inhibit endogenous peroxidase activity.
Then the sections were boiled in 10 mM citrate buffer,
pH 6.0, for 30 min or treated with formic acid for
3 min, for antigen retrieval. After rinsing in phosphate-
buffered saline (PBS), the sections were incubated with
normal horse serum for 2 h and then with the pri-
mary antibody overnight at 4◦C in humid chambers.
The following primary antibodies were used: anti-Aβ
(monoclonal mouse anti-human Aβ, Dako, Barcelona,
Spain), dilution 1:25, pretreated for 3 min with formic
acid; anti-GFAP (monoclonal mouse anti-human glial
fibrillary acidic protein, DAKOCYTOMATION), dilu-
tion 1:250, pretreated for 20 min with boiling citrate;
and anti-lectin of Lycopersicon esculentum (L-0651,
Sigma, Madrid, Spain), dilution 1:100, with no pre-
treatment.
The sections were washed three times in PBS and
immunostained by a standard avidin-biotin complex
method (secondary biotinylated universal Dako and
Streptavidin HRP, Dako), washed and finally treated for
3 min with 0.01% H2O2 and 0.05% diaminobenzidine
tetrahydrochloride (DAB, Sigma) for optical detection,
except for lectin, in which the sections were treated
only with streptavidin and DAB.
Western blot analysis
Nine TgFe, 8 TgSb, 6 WtFe, and 11 WtSb 6-month-
old mice were killed by rapid decapitation and all
brains were separated in regions and frozen in −80◦C.
Samples of the posterior hemisphere (including the
hippocampus) of all animals were homogenized in a
glass homogenizer in 600 µl of RIPA buffer (25 mM
Tris, HCl pH 7.6, 150 mM NaCl, 1%NP-40, 1% sodi-
um deoxyenolate, 0.1% SDS) with phosphatase in-
hibitors (complex mini-protease inhibitors 1:10 ml,
NaV 200 mM, NaF 1M, PMSF 10 0mM) and cen-
trifuged at 10,000 rpm for 5 min at 4◦C. Pellet fractions
were discarded and protein concentrations of the su-
pernatants were determined with the BCA method with
bovine serum albumin as a standard. Samples contain-
ing 20 µg of protein were loaded onto 10% acrylamide
gels. Proteins were separated by sodium dodecyl sul-
fate (SDS)-polyacrylamide gel electrophoresis (PAGE)
and electrophoretically transferred to nitrocellulose
membranes (400 mA for 90 min). Then the membranes
were incubated with 5% skimmed milk in TBS-T buffer
(100 mM Tris-buffered saline, 140 mM NaCl and 0.1%
Tween 20, pH 7.4) for 1 h at room temperature, and
incubated in primary antibody anti-GFAP (monoclon-
al mouse anti-human glial fibrillary acidic protein) di-
luted 1:3,000 in TBS-T containing 3% BSA (Sigma)
overnight at 4◦C. Subsequently, the membranes were
incubated with the secondary antibody (anti-rabbit) la-
beled with horseradish peroxidase (Dako) in a dilution
of 1:1,000. Finally, membranes were developed with
the chemiluminescence ECL Western blotting system
(Amersham/Pharmacia, Barcelona, Spain) followed by
apposition of the membranes to autoradiographic films
(Hyperfilm ECL, Amersham). The monoclonal an-
tibody to β-actin (Sigma) was used at a dilution of
1:5,000 as a control of protein loading.
Densitometry and statistical processing of data
The immunohistochemical images were captured us-
ing AxisVision AC Real 4.5 program, an inverted mi-
croscope with a 20x objective, and an AxioCam IC
Zeiss camera. The selection was made manually in-
cluding hippocampus or adjacent temporal cortex. To
analyze the image the Image J software was used
(http://www.uhnresearch.ca/facilities/wcif/fdownload.
html). For each image, color functions and color de-
convolution, H DAB vectors: color 2 R: 0.26814753,
G: 0.57031375, B: 0.77642715 were applied. The col-
or 2 image (brown) was inverted and the measurement
was obtained as a percentage of the DAB chromogen.
Data were expressed as mean ± standard error of the
mean (SEM). Comparisons between groups were per-
formed using the independent samples T-TEST. p val-
ues of less than 0.05 were considered statistically sig-
nificant and these are indicated in the figure as * p <
0.05 and ** p < 0.01.
Western blotting analysis was performed by mea-
suring protein levels using densitometry of all bands,
measured with Total Lab v2.01 software. The results
were normalized with β-actin. Data were expressed as
mean ± SEM. Comparisons among groups were per-
formed with a one-way analysis of variance (ANOVA)
followed by Tukey post-hoc test. p values of less than
0.05 were considered statistically significant and these
are indicated in the figure as * p < 0.05 and ** p <
0.01.
Mass spectrometry analysis of protein oxidative
damage markers
The same animals used for gel electrophoresis and
western blotting were utilized for the study of brain
lipid composition and oxidative stress markers (4 TgFe,
4 TgSb). The frontal and part of the parietal cortex
were used for study.
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The markers of protein oxidation – the protein car-
bonyls glutamic (GSA) and aminoadipic (AASA) semi-
aldehydes, glycoxidation (carboxyethyl-lysine CEL,
and carboxymethyl-lysine CML), and lipoxidation
(malondialdehydelysine MDAL, and CML) – were de-
termined by gas chromatography/mass spectrometry
(GC/MS). The trifluoroacetic acid methyl ester deriva-
tives of these five markers were measured in acid
hydrolyzed de-lipidated and reduced protein samples
using an isotope dilution method as previously de-
scribed [31], with an HP6890 Series II gas chromato-
graph (Agilent, Barcelona, Spain), an MSD5973A Se-
ries and a 7683 Series automatic injector, an HP-
5MS column (30-m x 0.25-mm x 0.25-µm), and the
described temperature program [31]. Quantification
was performed by external standardization using stan-
dard curves constructed from mixtures of deuterated
and non-deuterated standards. Analyses were carried
out by selected ion-monitoring GC/MS (SIM-GC/MS).
The ions used were lysine and [2H8]lysine, m/z
180 and 187, respectively; 5-hydroxy-2-aminovaleric
acid and [2H5]5-hydroxy-2-aminovaleric acid (stable
derivatives of GSA), m/z 280 and 285, respectively;
6-hydroxy-2-aminocaproic acid and [ 2H4]6-hydroxy-
2-aminocaproic acid (stable derivatives of AASA),
m/z 294 and 298, respectively; CML and [2H4]CML,
m/z 392 and 396, respectively; CEL and [2H4]CEL,
m/z 379 and 383, respectively; and MDAL and
[2H8]MDAL, m/z 474 and 482, respectively. The
amounts of product were expressed as the µmolar ratio
of GSA, AASA, CML, CEL, or MDAL/mol lysine.
Fatty acid analysis
Fatty acyl groups of brain lipids were analyzed as
methyl ester derivatives by GC/MS as previously de-
scribed [31]. Separation was performed in an SP2330
capillary column (30 m × 0.25 mm × 0.20 µm) in a
GC Hewlett Packard 6890 Series II gas chromatograph
(Agilent). A Hewlett Packard 5973A mass spectrom-
eter was used as detector in the electron-impact mode.
Identification of fatty acyl methyl esters was made by
comparison with authentic standards and on the basis
of mass spectra. Results are expressed as mol%. The
following fatty acyl indexes were also calculated: satu-
rated fatty acids (SFA); unsaturated fatty acids (UFA);
monounsaturated fatty acids (MUFA); polyunsaturat-
ed fatty acids from n-3 and n-6 series (PUFAn-3 and
PUFAn-6); average chain length (ACL) = [(Σ%Total14
× 14) + (Σ%Total16 × 16) + (Σ%Total18 x 18) +
(Σ%Total20 × 20) + (Σ%Total22 × 22)]/100]; double
bond index (DBI) = [(1 × Σmol% monoenoic) + (2
x Σmol% dienoic) + (3 × Σmol% trienoic) + (4 ×
Σmol% tetraenoic) + (5 ×Σmol% pentaenoic) + (6 ×
Σmol% hexaenoic)], and peroxidizability index (PI) =
[(0.025×Σmol% monoenoic)+ (1×Σmol% dienoic)
+ (2 × Σmol% trienoic) + (4 × Σmol% tetraenoic) +
(6 × Σmol% pentaenoic) + (8 × Σmol% hexaenoic)].
Statistical analyses
All values were expressed as means ± SEM. Com-
parisons between experimental groups were statistical-
ly analyzed with Student’s t tests. The minimum level




AβPP/PS1 mice treated neonatally either with iron or
vehicle and killed at six months presented Aβ plaques
in hippocampus (Fig. 1 a1, b1) and temporal cortex
(Fig. 1 a2, b2). Aβ plaques were not observed in
the hippocampus (Fig. 1 c1, d1) and temporal cortex
(Fig. 1 c2, d2) in Wt mice irrespectively of neonatal
treatments. No significant differences in the number of
plaques were seen in Tg mice treated with iron when
compared with Tg mice treated with vehicle alone (data
not shown).
In order to investigate the possibility of an inflamma-
tory reaction in the tissue, labeling of microglia cells
using lectin showed no differences between both Wt
and Tg mice groups at six months of age treated with
iron or sorbitol in the neonatal period.
In contrast, statistical analysis of densitometric im-
munohistochemistry for GFAP showed an increase in
GFAP levels in the hippocampus (p < 0.05), but not in
temporal cortex, in Wt mice that received iron in com-
parison to the group treated with vehicle alone in the
neonatal period (Fig. 2). Moreover, GFAP levels were
also significantly increased in the temporal cortex of
AβPP/PS1 mice treated with iron in comparison to the
Tg group treated with vehicle alone (p < 0.05) (Fig. 3).
Western blotting
In order to confirm immunohistochemical findings,
gel electrophoresis, and western blotting of total ho-
mogenates including the parietal cortex and hippocam-









Fig. 1. Representative histological sections of Aβ immunohistochemistry of hippocampus (1) and temporal cortex (2) of (a) TgFe group; (b)
TgSb group; (c) WtFe group; (d) WtSb group show amyloid plaques. Magnification: 20x. No differences among groups are observed.
pus was carried in Tg and Wt mice. Statistical com-
parison of GFAP band optic density normalized with
β-actin showed significant differences among the dif-
ferent groups. Tukey post hoc test revealed that iron
treatment in the neonatal period produced an increase
in GFAP expression levels in Wt mice when compared
with Wt mice treated with sorbitol alone (p < 0.01).
Increased GFAP expression was seen in Tg mice when
compared with Wt independently of neonatal iron ex-
posure (p < 0.01) (Fig. 4). Expression levels of GFAP
in Tg mice at six months treated with iron where high-
er, although not significantly so, when compared with
mice treated with sorbitol alone.
Fatty acid composition
Table 1 shows the fatty acid composition of brain lip-




























Fig. 2. Representative histological sections of GFAP immunohistochemistry of the hippocampus and temporal cortex of WtFe and WtSb groups
show immunostained astrocytes. Magnification: 20x (a). Statistical analysis reveals a significant increase in GFAP in the hippocampus of Wt
animals that received iron (* p < 0.05, independent samples t-test) (b).
ids from both untreated and transeated AβPP/PSIt
transgenic mice. Iron administration altered the fatty
acid composition of total brain lipids, so that the total
number of double bonds (DBI) and peroxidizability in-
dex (PI) was significantly decreased (p < 0.02 and p <
0.02, respectively). The fatty acids mainly responsible
for the decrease in DBI and PI were basically from the
PUFA n-3 series. Thus, iron transiently administered
at neonatal period significantly increased, at the age of
six months, the levels of saturated fatty acids such as





























Fig. 3. Representative histological sections of GFAP immunohistochemistry of the hippocampus and temporal cortex of TgFe and TgSb groups
show immunostained astrocytes. Magnification: 20x (a). A significant increase in GFAP is observed in the temporal cortex of transgenic animals
that received iron (**p < 0.01, independent samples t-test) (b).
16:0 (p < 0.03) and 18:0 (p = 0.05), whilst it decreased
the highly unsaturated eicosapentaenoic acid (20:5n-3)
and docosapentaenoic acids (22:5n-3). The content of
the highly unsaturated arachidonic acid (20:4n-6) and
docosahexaenoic acid (22:6n-3) maintained stable. No
changes were detected for monounsaturated fatty acids
and PUFA n-6 contents. The membrane acyl compo-
sition indicated that the membranes maintained a simi-
lar, even though slightly lower, fatty acid average chain
length (around 18 carbon atoms) in the Tg-Fe group














Tg-Fe    Tg-Sorb Wt-Fe   Wt-Sorb
GFAP 50kDa
Actin 45kDa
Fig. 4. Western blot analysis of GFAP in 1: WtSb (n = 11); 2: WtFe (n = 6); 3: TgSb (n = 8); and 4: TgFe (n = 9). Increased expression
levels of GFAP are seen in WtFe group versus WtSb, and in TgSb group versus WtSb; ** p < 0.001.
when compared with the group treated with sorbitol
alone.
Oxidative stress markers
Concerning the steady-state level of the protein ox-
idative damage markers, the concentrations of all the
five different oxidative (the specific protein carbonyls
GSA and AASA), glycoxidative (CEL and CML) and
lipoxidative (CML and MDAL) markers analyzed were
significantly decreased by iron treatment in the Tg ani-
mal group (Table 2). The mean magnitude of all these
decreases taken together was 23.0% in the brain of the
Tg treated with iron when compared with the group
treated with sorbitol alone.
DISCUSSION
The present findings have shown that transient iron
intake during neonatal period induces astrocytic gliosis
in AβPP/PS1 transgenic mice and in age-matched lit-
termates at the age of six months, and that this change is
not accompanied by apparent differences in microglial
reactions and, more particularly, in Aβ burden, as re-
vealed by the amount of Aβ plaques, in AβPP/PS1
transgenic mice at least, within the range of the period
studied. With minor differences, GFAP changes are
consistent with densitometry in GFAP immunostained
sections and gel electrophoresis and western blotting.
Administration of iron at very early stages of devel-
opment resulting in very similar effects in AβPP/PS1
and age-matched littermates points to the fact that Aβ
metabolism has no role in iron removal and later astro-
cytic responses in the neonatal period, in contrast to the
well-known interactions of Aβ and iron in older indi-
viduals [32]. Similarly, the lack of differences regard-
ing microglia does not give support to the concept that
soluble Aβ-metal complex may stimulate inflammato-
ry responses and thereby promote rapid phagocytosis
of the peptide [33].
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Table 1
Fatty acyl composition (%) of total lipids in the frontal cortex of
AβPP/PS1 transgenic mice treated with sorbitol (Tg sorbitol) or with
iron (TgFe) during the neonatal period and killed at six months of
age. Values are means ± SEM from n = 4 samples. ACL: aver-
age chain length; SFA: saturated fatty acids; UFA: unsaturated fatty
acids; MUFA: monounsaturated fatty acids; PUFAn = 3: polyunsat-
urated n-3 fatty acids; PUFAn-6: polyunsaturated n-6 fatty acids; PI:
peroxidizability index
Tg sorbitol Tg Fe pvalues
14:0 0.7 ± 0.1 0.6 ± 0.05 0.60
16:0 21.5 ± 0.6 25.4 ± 1.2 0.03
16:1n-7 0.5 ± 0.07 0.8 ± 0.15 0.14
18:0 19.2 ± 0.3 21.0 ± 0.7 0.05
18:1n-9 18.2 ± 0.4 18.5 ± 0.5 0.63
18:2n-6 4.3 ± 0.3 3.0 ± 0.2 0.01
18:3n-3 0.1 ± 0.02 0.9 ± 0.5 0.15
18:4n-6 0.2 ± 0.02 0.2 ± 0.03 0.63
20:0 0.3 ± 0.02 0.3 ± 0.1 0.618
20:1n-9 1.0 ± 0.05 1.1 ± 0.07 0.41
20:2n-6 0.3 ± 0.02 0.3 ± 0.08 0.44
20:3n-6 0.3 ± 0.04 0.3 ± 0.03 0.74
20:4n-6 7.3 ± 0.5 7.6 ± 0.3 0.56
20:5n-3 8.2 ± 1.3 4.8 ± 1.3 0.08
22:0 1.2 ± 0.1 0.9 ± 0.15 0.16
22:4n-6 2.4 ± 0.45 2.0 ± 0.04 0.42
22:5n-6 0.5 ± 0.1 0.4 ± 0.04 0.68
22:5n-3 2.3 ± 0.6 0.7 ± 0.1 0.03
24:0 0.7 ± 0.1 0.4 ± 0.1 0.05
22:6n-3 9.7 ± 1.5 9.9 ± 0.3 0.88
24:5n-3 0.5 ± 0.08 0.3 ± 0.05 0.10
24:6n-3 0.6 ± 0.1 0.4 ± 0.02 0.13
ACL 18.6 ± 0.04 18.4 ± 0.06 0.01
SFA 43.5 ± 0.8 48.7 ± 1.3 0.01
UFA 56.5 ± 0.8 51.3 ± 1.3 0.01
MUFA 19.8 ± 0.3 20.5 ± 0.6 0.33
PUFA 36.7 ± 0.7 30.9 ± 1.5 0.01
PUFAn-3 21.4 ± 0.6 17.0 ± 1.1 0.01
PUFAn-6 15.3 ± 0.7 13.8 ± 0.5 0.14
DBI 189.0 ± 4.4 163.2 ± 6.9 0.02
PI 196.7 ± 5.9 165.7 ± 8.7 0.02
Table 2
Markers of oxidative damage in frontal cortex in AβPP/PS1 mice
treated with iron (TgFe) in vehicle or with sorbitol alone (Tg sor-
bitol) in neonatal period and killed at the age of six months. Val-
ues are means ± SEM from n = 4 samples. GSA: Glutam-
ic semialdehyde; AASA: aminoadipic semialdehydes; CML: Nε-
carboxymethyl-lysine; CEL: Nε-carboxyethyl-lysine; MDAL: Nε-
malondialdehyde-lysine. Units: µmol/mol lysine
Tg Sorbitol Tg Fe p (Tg vs. TgFe)
GSA 6885.5 ± 314.5 5987.3 ± 155.0 0.03
AASA 86.9 ± 3.6 64.6 ± 2.9 0.001
CEL 270.2 ± 10.4 212.9 ± 6.8 0.002
CML 352.4 ± 25.2 233.1 ± 14.4 0.003
MDAL 1263.6 ± 96.2 938.0 ± 29.3 0.01
Acute and chronic brain insults trigger a specific glial
reaction, generally known as reactive astrogliosis, rep-
resented by a complex morphofunctional remodeling of
astrocytes [12]. GFAP expression also increases with
aging in the human brain; astrocytes may respond to
preclinical AD molecular pathology [34]. In line with
these observations in AD, recent studies have shown
that the number of astrocytes is significantly increased
in the hippocampus in AβPP/PS1 mice compared with
age- and gender-matched wild-type littermates [10].
Exactly the same results have been reproduced in the
present study, thus indicating that astrocytic gliosis is an
early event in the course of AβPP/PS1-related pathol-
ogy. Additionally, and critically, iron administration
during the neonatal period and later effects are inde-
pendent of the genetic substrate of the individual, as
similar astrocytic responses occur in AβPP/PS1 and
wild-type littermates.
The brain is unique in its homeostatic management
of iron in that saturation of iron-handling proteins can
occur more rapidly in the brain than in the peripheral
organs [20]. Iron accumulation and overload have been
identified as a severe toxic event affecting brain cells.
At certain iron concentrations, the defenses of brain
cells may fail, and homeostatic mechanisms are over-
whelmed. Under such conditions, differential cellular
responses in brain-associated cell types are recruited
to manage cell survival [20]. For instance, it has been
demonstrated that astrocytes are more resistant to free
iron toxicity than neurons and brain vascular endothe-
lial cells, and may even provide transient protection to
other cells within the brain [20]. A similar response
may also occur at less toxic doses of iron, thus ex-
plaining astrocytic reactions in adult animals following
neonatal administration of 10.0 mg/Kg of body weight
of iron carbonyl in postnatal days 12, 13, and 14.
Mechanisms leading to accompanying metabolic
changes in the brain of adult mice treated with iron in
the neonatal period are difficult to follow as a single
point at the age of six months is available for study in
AβPP/PS1 mice. Yet it can be assumed, as a work-
ing hypothesis, that iron treatment during the neonatal
period may enhance Fenton-type reactions, leading to
oxidative stress in this period. These reactions may be
followed by net flux of free radical generation leading
to protein modifications and membrane susceptibility
to lipid peroxidation, as well as qualitative and quanti-
tative changes in cell types. It has been demonstrated
that oxidative effects due to in vivo exposure to iron in-
volve not only Fenton reaction, but also complex mech-
anisms related to hormones release. Kokoszko et al.
demonstrated that in brain GH decreased whereas IGF-
1 increased basal oxidative lipid peroxidation after iron
injection in rats. In our experiment, GH would be a pro-
tector factor to early iron overload ingestion [35]. Con-
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cerning protein modifications, the percentage of change
in the five measured markers of protein oxidative
damage, resulting in reduced glutamic and aminoad-
ipic semialdehydes, Nε-carboxymethyl-lysine, Nε-
carboxyethyl-lysine and Nε-malondialdehyde-lysine,
is compatible with a homeostatic response to one-
time increased oxidative damage [36]. Similarly, the
changes in fatty acid composition are clearly compat-
ible with an adaptive response of brain to iron intake.
Thus, the depletion of 20 and 22 carbon n-3 precur-
sors would reflect an attempt to spare the levels of do-
cosahexaenoic acid. The conserved docosahexaenoic
levels, allowing for the essential functions of this fatty
acid in neurons, seem to confirm a successful response.
These changes in lipid composition lead to a lower
lipid peroxidizability, a fact that would also contribute
to reduced protein oxidative damage [37]. The results
of fatty acid analyses and levels of protein oxidative
damage are complementary, and, taken together, reflect
an adaptation to increased oxidative damage geared to
curve protein oxidative damage and lipid peroxidizabil-
ity. It was previously demonstrated that iron admin-
istration in the postnatal period induces mitochondrial
dysfunction in adult rats, with consequent increase in
superoxide production, which was accompanied by an
increase in SOD activity in cortex hippocampus and
substantia nigra, but not in striatum [29]. Thus, further
experiments aiming to investigate other possible alter-
ations induced by neonatal iron treatment in oxidative
parameters in transgenic mice are warranted.
Whether the changes found are specific to AβPP/PS1
transgenic mice is not known, but in all likelihood they
are not. Studies in a limited number of wild-type lit-
termates treated with iron or with sorbitol alone (n =
2 per group) showed a similar pattern as that observed
in AβPP/PS1 mice (unpublished observations).
In summary, the present study shows that increased
iron availability to the nervous tissue at early stages
of development in AβPP/PS1 mice results in signifi-
cant cellular (increased astrocytes and increased GFAP
expression levels) and metabolic (brain lipid composi-
tion, and reduced index of peroxidizability and oxida-
tive protein damage) responses that are maintained lat-
er in life. Although these results suggest a permanent
cellular and molecular defense to transient iron over-
load during development, it may be questioned whether
these changes are protective or facilitators of later brain
damage. The absence of increased microglial respons-
es, the lack of increased amyloid burden, together with
reduced index of lipid peroxidizability and oxidative
protein damage in iron-treated mice, are indicators of a
scenario consistent with reduced vulnerability to oxida-
tive stress. Yet increased astrocytic gliosis usually re-
flects impaired neuronal/glial homeostasis [12,34,38].
It is well documented that perinatal iron deficiency is
causative of brain damage persisting into adult life [39–
43]. The present findings clearly document that excess
of iron during the neonatal period also impacts in the
cellular and molecular composition of the adult brain.
Furthermore, early Fe administration during develop-
ment does not interfere with the appearance of amyloid
plaques in AβPP/PS1 transgenic mice.
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